Skip to main content
Top
Published in: CEN Case Reports 2/2017

01-11-2017 | Case report

Urinary mulberry cells and mulberry bodies are useful tool to detect late-onset Fabry disease

Authors: Homare Shimohata, Hiroshi Maruyama, Yasunori Miyamoto, Mamiko Takayasu, Kouichi Hirayama, Masaki Kobayashi

Published in: CEN Case Reports | Issue 2/2017

Login to get access

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by a lack of α-galactosidase A activity, which leads to the accumulation of globotriaosylceramide in various organs. A complete lack of α-galactosidase A activity in a hemizygous male is the classical phenotype, and some hemizygous males show primarily cardiac and/or renal symptoms that appear in adulthood; this is called the variant type or the late-onset type. The kidney and heart are the major target organs, with damage to these organs related to mortality. Thus, in Fabry patients, early detection and early treatment are critical to longevity. Here, we present a 55-year-old Japanese male patient who was diagnosed with late-onset Fabry nephropathy with cardiomyopathy but with no abnormal urinary findings except for urinary mulberry cells and mulberry bodies. In spite of the absence of abnormal urinary findings, the light microscopic and electron microscopic pathological findings showed extensive deposition of globotriaosylceramide to podocytes. In this paper, we propose that the presence of mulberry cells and mulberry bodies can be used for the earlier detection of Fabry nephropathy, especially the late-onset type.
Literature
1.
go back to reference Kint JA. Fabry’s disease: alpha-galactosidase deficiency. Science. 1970;167:1268–9.CrossRef Kint JA. Fabry’s disease: alpha-galactosidase deficiency. Science. 1970;167:1268–9.CrossRef
2.
go back to reference Tondel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24:137–8.CrossRef Tondel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24:137–8.CrossRef
3.
go back to reference Pisani A, Visciano B, Imbriaco M, et al. The kidney in Fabry’s disease. Clin Genet. 2014;86:301–9.CrossRef Pisani A, Visciano B, Imbriaco M, et al. The kidney in Fabry’s disease. Clin Genet. 2014;86:301–9.CrossRef
4.
go back to reference Terryn W, Cochat P, Froissart R, et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant. 2013;28:505–17.CrossRef Terryn W, Cochat P, Froissart R, et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant. 2013;28:505–17.CrossRef
5.
go back to reference Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol. 2008;4:327–36.CrossRef Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol. 2008;4:327–36.CrossRef
6.
go back to reference Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–93.CrossRef Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–93.CrossRef
7.
go back to reference Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64:801–7.CrossRef Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64:801–7.CrossRef
8.
go back to reference Tondel C, Kanai T, Larsen KK, et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron. 2015;129:16–21.CrossRef Tondel C, Kanai T, Larsen KK, et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron. 2015;129:16–21.CrossRef
9.
go back to reference Eng CE, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:182.CrossRef Eng CE, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30:182.CrossRef
10.
go back to reference Trimarchi H, Canzonieri R, Muryan A, et al. Copious podocyturia without proteinuria and with normal renal function in a young adult with Fabry disease. Case Rep Nephrol. 2015;257628. Trimarchi H, Canzonieri R, Muryan A, et al. Copious podocyturia without proteinuria and with normal renal function in a young adult with Fabry disease. Case Rep Nephrol. 2015;257628.
11.
go back to reference Becher GJ, Nicholls K. Lipiduria-with special relevance to Fabry disease. Clin Chem Lab Med. 2015;53:s1465–70. Becher GJ, Nicholls K. Lipiduria-with special relevance to Fabry disease. Clin Chem Lab Med. 2015;53:s1465–70.
12.
go back to reference Nakamichi T, Miyazaki M, Nakayama K, et al. Fabry’s disease discovered with chance urinary mulberry cells: a case report. CEN Case Rep. 2013;2:49–52.CrossRef Nakamichi T, Miyazaki M, Nakayama K, et al. Fabry’s disease discovered with chance urinary mulberry cells: a case report. CEN Case Rep. 2013;2:49–52.CrossRef
13.
go back to reference Honda T, Komatsu E, Furuse S, Mise N. Fabry disease diagnosed based on the detection of urinary mulberry bodies. Int Med. 2016;55:2903.CrossRef Honda T, Komatsu E, Furuse S, Mise N. Fabry disease diagnosed based on the detection of urinary mulberry bodies. Int Med. 2016;55:2903.CrossRef
14.
go back to reference Shimohata H, Ogawa Y, Maruyama H, Hirayama K, Kobayashi M. A case of renal variant of Fabry disease diagnosed by the presence of urinary mulberry cells. Int Med. 2016;55:3475–8.CrossRef Shimohata H, Ogawa Y, Maruyama H, Hirayama K, Kobayashi M. A case of renal variant of Fabry disease diagnosed by the presence of urinary mulberry cells. Int Med. 2016;55:3475–8.CrossRef
15.
go back to reference Najafian B, Svarstad E, Bostad L, et al. Progressive podocyte injury and globotriaosylceramide (Gb-3) accumulation in young patients with Fabry disease. Kidney Int. 2010;79:663–70.CrossRef Najafian B, Svarstad E, Bostad L, et al. Progressive podocyte injury and globotriaosylceramide (Gb-3) accumulation in young patients with Fabry disease. Kidney Int. 2010;79:663–70.CrossRef
16.
go back to reference Tondel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51:767–76.CrossRef Tondel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51:767–76.CrossRef
Metadata
Title
Urinary mulberry cells and mulberry bodies are useful tool to detect late-onset Fabry disease
Authors
Homare Shimohata
Hiroshi Maruyama
Yasunori Miyamoto
Mamiko Takayasu
Kouichi Hirayama
Masaki Kobayashi
Publication date
01-11-2017
Publisher
Springer Singapore
Published in
CEN Case Reports / Issue 2/2017
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-017-0262-5

Other articles of this Issue 2/2017

CEN Case Reports 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.